Most Read Articles
11 Oct 2018
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
10 May 2019
Increases in levels of high-density lipoprotein (HDL-C) but not low-density lipoprotein or total cholesterol after 24 weeks of tofacitinib treatment translate to a lower risk of future major adverse cardiovascular events, according to a study.
Roshini Claire Anthony, 4 days ago

Patients with type 2 diabetes (T2D) and high cardiovascular (CV) risk do not have an elevated risk of major adverse CV events (MACE)* when taking oral semaglutide alongside standard-of-care (SOC) therapy, according to findings of the PIONEER 6** trial presented at ADA 2019.

Superoxide dismutase: keeping cells rejuvenated

Rachel Soon
Medical Writer
12 Dec 2018

As we age, a wide range of stress factors from the environment around us can have a slow but cumulative detrimental effect on the body, even in the absence of specific disease. This manifests primarily in oxidative damage to various proteins and other components in our cells. In our December issue, MIMS Pharmacist shines a Spotlight on superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Oct 2018
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
10 May 2019
Increases in levels of high-density lipoprotein (HDL-C) but not low-density lipoprotein or total cholesterol after 24 weeks of tofacitinib treatment translate to a lower risk of future major adverse cardiovascular events, according to a study.
Roshini Claire Anthony, 4 days ago

Patients with type 2 diabetes (T2D) and high cardiovascular (CV) risk do not have an elevated risk of major adverse CV events (MACE)* when taking oral semaglutide alongside standard-of-care (SOC) therapy, according to findings of the PIONEER 6** trial presented at ADA 2019.